The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment

Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vaccine, on da...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Gavriatopoulou, Maria, Ntanasis-Stathopoulos, Ioannis, Briasoulis, Alexandros, Gumeni, Sentiljana, Malandrakis, Panagiotis, Fotiou, Despina, Papanagnou, Eleni-Dimitra, Migkou, Magdalini, Theodorakakou, Foteini, Roussou, Maria, Eleutherakis-Papaiakovou, Evangelos, Kanellias, Nikolaos, Trougakos, Ioannis P., Kastritis, Efstathios, Dimopoulos, Meletios A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327056/
https://www.ncbi.nlm.nih.gov/pubmed/34341335
http://dx.doi.org/10.1038/s41408-021-00530-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327056/
https://www.ncbi.nlm.nih.gov/pubmed/34341335
http://dx.doi.org/10.1038/s41408-021-00530-3

Ejemplares similares